2020 journal article
Modelling future usage and cost of factor and emicizumab to treat haemophilia A for the US Western States Region IX haemophilia treatment centres
Haemophilia, 27(1).
author keywords: cost; decision analysis; emicizumab; epidemiology; haemophilia A; treatment; usage
MeSH headings : Antibodies, Bispecific; Antibodies, Monoclonal, Humanized; Factor VIII; Hemophilia A / drug therapy; Humans; Retrospective Studies
TL;DR:
Increased usage of emicizumab in the United States will affect standard half‐life (SHL) and extended half-life (EHL) products usage and cost.
(via Semantic Scholar)
UN Sustainable Development Goal Categories
3. Good Health and Well-being
(Web of Science; OpenAlex)
Source: ORCID
Added: October 5, 2020
Increased usage of emicizumab in the United States will affect standard half‐life (SHL) and extended half‐life (EHL) products usage and cost.